{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:25Z","timestamp":1786979605940,"version":"build-2736575974"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00066-025-02501-0","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:20:56Z","timestamp":1769167256000},"page":"456-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated approaches to sensitizing melanoma to radiotherapy"],"prefix":"10.1007","volume":"202","author":[{"given":"Abdullah A.","family":"Aseeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"AlKhafaje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Abdul-Reda Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola Kamal A.","family":"Alkadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aldulaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir","family":"Mahmood Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waam Mohammed","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Smerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2501_CR1","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.3390\/cancers14194652","volume":"14","author":"J Lopes","year":"2022","unstructured":"Lopes\u00a0J, Rodrigues\u00a0C, Gaspar\u00a0M, Reis\u00a0C (2022) Melanoma management: from epidemiology to treatment and latest advances. Cancers 14:4652","journal-title":"Cancers"},{"issue":"3","key":"2501_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40257-017-0325-6","volume":"19","author":"EA Rozeman","year":"2018","unstructured":"Rozeman\u00a0EA, Dekker\u00a0TJ, Haanen\u00a0JB, Blank\u00a0CU (2018) Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am J Clin Dermatol 19(3):303\u2013317","journal-title":"Am J Clin Dermatol"},{"key":"2501_CR3","doi-asserted-by":"crossref","unstructured":"Domingues B, Lopes JM, Soares P, P\u00f3pulo H (2018) Melanoma treatment in review. ITT: 35\u201349","DOI":"10.2147\/ITT.S134842"},{"issue":"19","key":"2501_CR4","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/cancers16193304","volume":"16","author":"O Azem","year":"2024","unstructured":"Azem\u00a0O, Nabulsi\u00a0O, Jelinek\u00a0M, Joshi\u00a0N (2024) Radiation therapy in the management of head and neck mucosal melanoma. Cancers 16(19):3304","journal-title":"Cancers"},{"issue":"1","key":"2501_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13014-020-01501-x","volume":"15","author":"J Haussmann","year":"2020","unstructured":"Haussmann\u00a0J, Corradini\u00a0S, Nestle-Kraemling\u00a0C, B\u00f6lke\u00a0E, Njanang\u00a0FJD, Tamaskovics\u00a0B, Orth\u00a0K, Ruckhaeberle\u00a0E, Fehm\u00a0T, Mohrmann\u00a0S (2020) Recent advances in radiotherapy of breast cancer. Radiat Oncol 15(1):71","journal-title":"Radiat Oncol"},{"issue":"1","key":"2501_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/IIO.0000000000000153","volume":"57","author":"RW Milam Jr","year":"2017","unstructured":"Milam\u00a0RW Jr, Batson\u00a0SA, Breazzano\u00a0MP, Ayala-Peacock\u00a0DN, Daniels\u00a0AB (2017) Modern and novel radiotherapy approaches for the treatment of uveal melanoma. Int Ophthalmol Clin 57(1):11\u201327","journal-title":"Int Ophthalmol Clin"},{"key":"2501_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2016.12.003","volume":"110","author":"S Espenel","year":"2017","unstructured":"Espenel\u00a0S, Vallard\u00a0A, Rancoule\u00a0C, Garcia\u00a0M\u2011A, Guy\u00a0J\u2011B, Chargari\u00a0C, Deutsch\u00a0E, Magn\u00e9\u00a0N (2017) Melanoma: Last call for radiotherapy. Crit Rev Oncol Hematol 110:13\u201319","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2501_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3171\/2016.9.JNS161585","volume":"127","author":"O Cohen-Inbar","year":"2017","unstructured":"Cohen-Inbar\u00a0O, Shih\u00a0H\u2011H, Xu\u00a0Z, Schlesinger\u00a0D, Sheehan\u00a0JP (2017) The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. JNS 127(5):1007\u20131014","journal-title":"JNS"},{"issue":"9","key":"2501_CR9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson\u00a0MA, Burmeister\u00a0BH, Ainslie\u00a0J, Fisher\u00a0R, Di Iulio\u00a0J, Smithers\u00a0BM, Hong\u00a0A, Shannon\u00a0K, Scolyer\u00a0RA, Carruthers\u00a0S (2015) Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6\u2011year follow-up of a\u00a0phase\u00a03, randomised controlled trial. Lancet Oncol 16(9):1049\u20131060","journal-title":"Lancet Oncol"},{"issue":"3","key":"2501_CR10","doi-asserted-by":"publisher","first-page":"1903827","DOI":"10.1080\/21645515.2021.1903827","volume":"18","author":"L Tagliaferri","year":"2022","unstructured":"Tagliaferri\u00a0L, Lancellotta\u00a0V, Fionda\u00a0B, Mangoni\u00a0M, Cas\u00e0\u00a0C, Di Stefani\u00a0A, Pagliara\u00a0MM, D\u2019Aviero\u00a0A, Schinzari\u00a0G, Chiesa\u00a0S (2022) Immunotherapy and radiotherapy in melanoma: a\u00a0multidisciplinary comprehensive review. Hum Vaccines Immunother 18(3):1903827","journal-title":"Hum Vaccines Immunother"},{"issue":"5","key":"2501_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CMR.0000000000000761","volume":"31","author":"Y Ge","year":"2021","unstructured":"Ge\u00a0Y, Che\u00a0X, Gao\u00a0X, Zhao\u00a0S, Su\u00a0J (2021) Combination of radiotherapy and targeted therapy for melanoma brain metastases: a\u00a0systematic review. Melanoma Res 31(5):413\u2013420","journal-title":"Melanoma Res"},{"issue":"3","key":"2501_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.survophthal.2016.12.012","volume":"62","author":"M Popovic","year":"2017","unstructured":"Popovic\u00a0M, Ahmed\u00a0IIK, DiGiovanni\u00a0J, Shields\u00a0CL (2017) Radiotherapeutic and surgical management of iris melanoma: a\u00a0review. Surv Ophthalmol 62(3):302\u2013311","journal-title":"Surv Ophthalmol"},{"key":"2501_CR13","doi-asserted-by":"publisher","first-page":"vi22","DOI":"10.1093\/annonc\/mdp257","volume":"20","author":"A Testori","year":"2009","unstructured":"Testori\u00a0A, Rutkowski\u00a0P, Marsden\u00a0J, Bastholt\u00a0L, Chiarion-Sileni\u00a0V, Hauschild\u00a0A (2009) Eggermont AMM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 20:vi22\u2013vi29","journal-title":"Ann Oncol"},{"issue":"1","key":"2501_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13014-020-01615-2","volume":"15","author":"A Hendrickx","year":"2020","unstructured":"Hendrickx\u00a0A, Cozzio\u00a0A, Plasswilm\u00a0L, Panje\u00a0CM (2020) Radiotherapy for lentigo maligna and lentigo maligna melanoma\u2014a\u00a0systematic review. Radiat Oncol 15(1):174","journal-title":"Radiat Oncol"},{"issue":"1","key":"2501_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hed.26470","volume":"43","author":"MC Grant-Freemantle","year":"2021","unstructured":"Grant-Freemantle\u00a0MC, O\u2019Neill\u00a0LB, Clover\u00a0AJP (2021) The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: systematic review and meta-analysis. Head & Neck 43(1):323\u2013333","journal-title":"Head & Neck"},{"issue":"4","key":"2501_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/229255031101900405","volume":"19","author":"A Hallock","year":"2011","unstructured":"Hallock\u00a0A, Vujovic\u00a0O, Yu\u00a0E (2011) Is radiotherapy an effective treatment option for recurrent metastatic malignant melanoma? A\u00a0case report of short-course, large-fraction radiation and a\u00a0literature review. Can J Plast Surg 19(4):153\u2013155","journal-title":"Can J Plast Surg"},{"issue":"3","key":"2501_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/annonc\/mdv622","volume":"27","author":"K Ahmed","year":"2016","unstructured":"Ahmed\u00a0K, Stallworth\u00a0D, Kim\u00a0Y, Johnstone\u00a0P, Harrison\u00a0L, Caudell\u00a0J, Yu\u00a0H, Etame\u00a0A, Weber\u00a0J, Gibney\u00a0G (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1\u00a0therapy. Ann Oncol 27(3):434\u2013441","journal-title":"Ann Oncol"},{"issue":"33","key":"2501_CR18","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.19.01414","volume":"37","author":"AM Hong","year":"2019","unstructured":"Hong\u00a0AM, Fogarty\u00a0GB, Dolven-Jacobsen\u00a0K, Burmeister\u00a0BH, Lo\u00a0SN, Haydu\u00a0LE, Vardy\u00a0JL, Nowak\u00a0AK, Dhillon\u00a0HM, Ahmed\u00a0T (2019) Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a\u00a0multicenter, randomized phase\u00a0III trial. J\u00a0Clin Oncol 37(33):3132\u20133141","journal-title":"J Clin Oncol"},{"issue":"1","key":"2501_CR19","first-page":"9435389","volume":"2019","author":"SJ Rogers","year":"2019","unstructured":"Rogers\u00a0SJ, Puric\u00a0E, Eberle\u00a0B, Datta\u00a0NR, Bodis\u00a0SB (2019) Radiotherapy for melanoma: More than DNA damage. Dermatol Res Pract 2019(1):9435389","journal-title":"Dermatol Res Pract"},{"key":"2501_CR20","doi-asserted-by":"publisher","first-page":"108632","DOI":"10.1016\/j.clineuro.2024.108632","volume":"248","author":"C Weber-Levine","year":"2025","unstructured":"Weber-Levine\u00a0C, Jiang\u00a0K, Al-Mistarehi\u00a0A\u2011H, Welland\u00a0J, Hersh\u00a0AM, Horowitz\u00a0MA, Davidar\u00a0AD, Sattari\u00a0SA, Redmond\u00a0KJ, Lee\u00a0SH (2025) The role of combination surgery and radiotherapy in patients with metastatic spinal cord compression: What are the remaining grey areas? A\u00a0systematic review. Clin Neurol Neurosurg 248:108632","journal-title":"Clin Neurol Neurosurg"},{"key":"2501_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fcell.2020.00041","volume":"8","author":"J Sia","year":"2020","unstructured":"Sia\u00a0J, Szmyd\u00a0R, Hau\u00a0E, Gee\u00a0HE (2020) Molecular mechanisms of radiation-induced cancer cell death: a\u00a0primer. Front Cell Dev Biol 8:41","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2501_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/2159-8290.CD-22-0787","volume":"13","author":"P Dharanipragada","year":"2023","unstructured":"Dharanipragada\u00a0P, Zhang\u00a0X, Liu\u00a0S, Lomeli\u00a0SH, Hong\u00a0A, Wang\u00a0Y, Yang\u00a0Z, Lo\u00a0KZ, Vega-Crespo\u00a0A, Ribas\u00a0A (2023) Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma. Cancer Discov 13(4):880\u2013909","journal-title":"Cancer Discov"},{"key":"2501_CR23","first-page":"e934116","volume":"27","author":"W Boulefour","year":"2021","unstructured":"Boulefour\u00a0W, Rowinski\u00a0E, Louati\u00a0S, Sotton\u00a0S, Wozny\u00a0A\u2011S, Moreno-Acosta\u00a0P, Mery\u00a0B, Rodriguez-Lafrasse\u00a0C, Magne\u00a0N (2021) A\u00a0review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit Int Med J Exp Clin Res 27:e934116\u2013934111","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"issue":"14","key":"2501_CR24","doi-asserted-by":"publisher","first-page":"7755","DOI":"10.3390\/ijms22147755","volume":"22","author":"V Trappetti","year":"2021","unstructured":"Trappetti\u00a0V, Fazzari\u00a0JM, Fernandez-Palomo\u00a0C, Scheidegger\u00a0M, Volarevic\u00a0V, Martin\u00a0OA, Djonov\u00a0VG (2021) Microbeam radiotherapy\u2014a novel therapeutic approach to overcome radioresistance and enhance anti-tumour response in melanoma. Int J Mol Sci 22(14):7755","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2501_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12967-017-1123-x","volume":"15","author":"K De Wolf","year":"2017","unstructured":"De Wolf\u00a0K, Kruse\u00a0V, Sundahl\u00a0N, Van Gele\u00a0M, Chevolet\u00a0I, Speeckaert\u00a0R, Brochez\u00a0L, Ost\u00a0P (2017) A\u00a0phase\u00a0II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J\u00a0Transl Med 15(1):21","journal-title":"J Transl Med"},{"key":"2501_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.radonc.2021.01.030","volume":"157","author":"JG van Beek","year":"2021","unstructured":"van Beek\u00a0JG, Ramdas\u00a0WD, Angi\u00a0M, van Rij\u00a0CM, Naus\u00a0NC, Kacperek\u00a0A, Errington\u00a0RD, Damato\u00a0B, Heimann\u00a0H, Kili\u00e7\u00a0E (2021) Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma. Radiother Oncol 157:219\u2013224","journal-title":"Radiother Oncol"},{"key":"2501_CR27","doi-asserted-by":"publisher","first-page":"106807","DOI":"10.1016\/j.intimp.2020.106807","volume":"87","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh\u00a0M, Farhood\u00a0B, Musa\u00a0AE, Taeb\u00a0S, Najafi\u00a0M (2020) The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives. Int Immunopharmacol 87:106807","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"2501_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1080\/1061186X.2024.2384071","volume":"32","author":"J Wang","year":"2024","unstructured":"Wang\u00a0J, Wang\u00a0Y, Jiang\u00a0X (2024) Targeting anticancer immunity in melanoma tumour microenvironment: unleashing the potential of adjuvants, drugs, and phytochemicals. J\u00a0Drug Target 32(9):1052\u20131072","journal-title":"J Drug Target"},{"issue":"1","key":"2501_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"R-X Huang","year":"2020","unstructured":"Huang\u00a0R\u2011X, Zhou\u00a0P\u2011K (2020) DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 5(1):60","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"2501_CR30","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.3390\/cancers17172787","volume":"17","author":"T Zheng","year":"2025","unstructured":"Zheng\u00a0T, Sun\u00a0C, Yun\u00a0C, Wang\u00a0H, Liu\u00a0X (2025) Unlocking the Therapeutic Potential of DNA-PKcs in Cancer: Comprehensive Insights into Mechanisms and Clinical Applications. Cancers 17(17):2787","journal-title":"Cancers"},{"key":"2501_CR31","doi-asserted-by":"publisher","first-page":"1234973","DOI":"10.3389\/fphar.2023.1234973","volume":"14","author":"C Sun","year":"2023","unstructured":"Sun\u00a0C, Chu\u00a0A, Song\u00a0R, Liu\u00a0S, Chai\u00a0T, Wang\u00a0X, Liu\u00a0Z (2023) PARP inhibitors combined with radiotherapy: are we ready? Front Pharmacol 14:1234973","journal-title":"Front Pharmacol"},{"issue":"7","key":"2501_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/09553002.2018.1478160","volume":"94","author":"P Bhattacharya","year":"2018","unstructured":"Bhattacharya\u00a0P, Shetake\u00a0NG, Pandey\u00a0BN, Kumar\u00a0A (2018) Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization. Int J Radiat Biol 94(7):628\u2013644","journal-title":"Int J Radiat Biol"},{"issue":"9","key":"2501_CR33","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00262-020-02587-8","volume":"69","author":"T Watanabe","year":"2020","unstructured":"Watanabe\u00a0T, Firat\u00a0E, Scholber\u00a0J, Gaedicke\u00a0S, Heinrich\u00a0C, Luo\u00a0R, Ehrat\u00a0N, Multhoff\u00a0G, Schmitt-Graeff\u00a0A, Grosu\u00a0A\u2011L (2020) Deep abscopal response to radiotherapy and anti-PD\u20111 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunol Immunother 69(9):1823\u20131832","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2501_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13046-021-02000-x","volume":"40","author":"I Telarovic","year":"2021","unstructured":"Telarovic\u00a0I, Wenger\u00a0RH, Pruschy\u00a0M (2021) Interfering with tumor hypoxia for radiotherapy optimization. J\u00a0Exp Clin Cancer Res 40(1):197","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2501_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2015.2","volume":"16","author":"WP Roos","year":"2016","unstructured":"Roos\u00a0WP, Thomas\u00a0AD, Kaina\u00a0B (2016) DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer 16(1):20\u201333","journal-title":"Nat Rev Cancer"},{"key":"2501_CR36","doi-asserted-by":"publisher","first-page":"1390518","DOI":"10.3389\/fonc.2024.1390518","volume":"14","author":"D Iglesias-Corral","year":"2024","unstructured":"Iglesias-Corral\u00a0D, Garc\u00eda-Valles\u00a0P, Arroyo-Garrapucho\u00a0N, Bueno-Mart\u00ednez\u00a0E, Ruiz-Robles\u00a0JM, Ovejero-S\u00e1nchez\u00a0M, Gonzalez-Sarmiento\u00a0R, Herrero\u00a0AB (2024) Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death. Front Oncol 14:1390518","journal-title":"Front Oncol"},{"issue":"9","key":"2501_CR37","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/mc.23329","volume":"60","author":"V Gopalakrishnan","year":"2021","unstructured":"Gopalakrishnan\u00a0V, Sharma\u00a0S, Ray\u00a0U, Manjunath\u00a0M, Lakshmanan\u00a0D, Vartak\u00a0SV, Gopinatha\u00a0VK, Srivastava\u00a0M, Kempegowda\u00a0M, Choudhary\u00a0B (2021) SCR7, an inhibitor of NHEJ can sensitize tumor cells to ionization radiation. Mol Carcinog 60(9):627\u2013643","journal-title":"Mol Carcinog"},{"issue":"6","key":"2501_CR38","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/09553002.2021.1956001","volume":"99","author":"JA Nickoloff","year":"2023","unstructured":"Nickoloff\u00a0JA, Sharma\u00a0N, Allen\u00a0CP, Taylor\u00a0L, Allen\u00a0SJ, Jaiswal\u00a0AS, Hromas\u00a0R (2023) Roles of homologous recombination in response to ionizing radiation-induced DNA damage. Int J Radiat Biol 99(6):903\u2013914","journal-title":"Int J Radiat Biol"},{"issue":"10","key":"2501_CR39","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/exd.14877","volume":"32","author":"H Im","year":"2023","unstructured":"Im\u00a0H, Lee\u00a0J, Lee\u00a0HJ, Kim\u00a0DY, Kim\u00a0EJ, Yi\u00a0JY (2023) Cyclin D1 promotes radioresistance through regulation of RAD51 in melanoma. Exp Dermatol 32(10):1706\u20131716","journal-title":"Exp Dermatol"},{"issue":"6","key":"2501_CR40","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/genes12060925","volume":"12","author":"E-M Faulhaber","year":"2021","unstructured":"Faulhaber\u00a0E\u2011M, Jost\u00a0T, Symank\u00a0J, Scheper\u00a0J, B\u00fcrkel\u00a0F, Fietkau\u00a0R, Hecht\u00a0M, Distel\u00a0LV (2021) Kinase inhibitors of DNA-PK, ATM and ATR in combination with ionizing radiation can increase tumor cell death in HNSCC cells while sparing normal tissue cells. Genes 12(6):925","journal-title":"Genes"},{"issue":"9","key":"2501_CR41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.tcb.2022.04.010","volume":"32","author":"KW Caldecott","year":"2022","unstructured":"Caldecott\u00a0KW (2022) DNA single-strand break repair and human genetic disease. Trends Cell Biol 32(9):733\u2013745","journal-title":"Trends Cell Biol"},{"issue":"1","key":"2501_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/med.22069","volume":"45","author":"YR Bai","year":"2025","unstructured":"Bai\u00a0YR, Yang\u00a0WG, Jia\u00a0R, Sun\u00a0JS, Shen\u00a0DD, Liu\u00a0HM, Yuan\u00a0S (2025) The recent advance and prospect of poly (ADP-ribose) polymerase inhibitors for the treatment of cancer. Med Res Rev 45(1):214\u2013273","journal-title":"Med Res Rev"},{"key":"2501_CR43","doi-asserted-by":"crossref","unstructured":"Yang F, Song H, Wu W, Guo J (2025) Targets and promising adjuvants for improving breast tumor response to radiotherapy. Bioorg Chem: 108582","DOI":"10.1016\/j.bioorg.2025.108582"},{"issue":"12","key":"2501_CR44","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00066-022-02009-x","volume":"199","author":"J Scheper","year":"2023","unstructured":"Scheper\u00a0J, Hildebrand\u00a0LS, Faulhaber\u00a0EM, Deloch\u00a0L, Gaipl\u00a0US, Symank\u00a0J, Fietkau\u00a0R, Distel\u00a0LV, Hecht\u00a0M, Jost\u00a0T (2023) Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts. Strahlenther Onkol 199(12):1128\u20131139","journal-title":"Strahlenther Onkol"},{"issue":"12_Supplement","key":"2501_CR45","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1158\/1538-7445.AM2022-3305","volume":"82","author":"AM Tuma","year":"2022","unstructured":"Tuma\u00a0AM, Zhong\u00a0W, Liu\u00a0L, Burgenske\u00a0DM, Carlson\u00a0BL, Bakken\u00a0KK, Hu\u00a0Z, Connors\u00a0MA, Sarkaria\u00a0JN (2022) Abstract 3305: WSD-0628, a\u00a0novel brain penetrant ATM inhibitor, radiosensitizes GBM and melanoma patient derived xenografts. Cancer Res 82(12_Supplement):3305\u20133305","journal-title":"Cancer Res"},{"key":"2501_CR46","doi-asserted-by":"crossref","unstructured":"Jin WJ, Zangl LM, Hyun M, Massoud E, Schroeder K, Alexandridis RA, Morris ZS (2023) ATM inhibition augments type\u00a0I interferon response and antitumor T\u2011cell immunity when combined with radiation therapy in murine tumor models. J\u00a0Immunother Cancer 11(9)","DOI":"10.1136\/jitc-2023-007474"},{"issue":"19","key":"2501_CR47","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap\u00a0TA, Krebs\u00a0MG, Postel-Vinay\u00a0S, El-Khouiery\u00a0A, Soria\u00a0JC, Lopez\u00a0J, Berges\u00a0A, Cheung\u00a0SYA, Irurzun-Arana\u00a0I, Goldwin\u00a0A, Felicetti\u00a0B, Jones\u00a0GN, Lau\u00a0A, Frewer\u00a0P, Pierce\u00a0AJ, Clack\u00a0G, Stephens\u00a0C, Smith\u00a0SA, Dean\u00a0E, Ceralasertib\u00a0HSJ (2021) an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A\u00a0Phase\u00a0I Study. Clin Cancer Res 27(19):5213\u20135224","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2501_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.31661\/jbpe.v0i0.1912-1000","volume":"12","author":"M Talebpoor","year":"2022","unstructured":"Talebpoor\u00a0M, Neshasteh-Riz\u00a0A, Koosha\u00a0F, Eynali\u00a0S (2022) The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma. J\u00a0Biomed Phys Eng 12(3):267\u2013276","journal-title":"J Biomed Phys Eng"},{"issue":"2","key":"2501_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim\u00a0R, Kwon\u00a0M, An\u00a0M, Kim\u00a0S, Smith\u00a0S, Loemb\u00e9\u00a0A, Mortimer\u00a0P, Armenia\u00a0J, Lukashchuk\u00a0N, Shah\u00a0N (2022) Phase\u00a0II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1\u00a0therapy. Ann Oncol 33(2):193\u2013203","journal-title":"Ann Oncol"},{"issue":"6","key":"2501_CR50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/genes12060849","volume":"12","author":"S Jonuscheit","year":"2021","unstructured":"Jonuscheit\u00a0S, Jost\u00a0T, Gajdo\u0161ov\u00e1\u00a0F, Wrobel\u00a0M, Hecht\u00a0M, Fietkau\u00a0R, Distel\u00a0L (2021) PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation. Genes 12(6):849","journal-title":"Genes"},{"key":"2501_CR51","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fmed.2023.1149918","volume":"10","author":"M Sabbah","year":"2023","unstructured":"Sabbah\u00a0M, Najem\u00a0A, Vanderkerkhove\u00a0C, Kert\u00a0F, Jourani\u00a0Y, Journe\u00a0F, Awada\u00a0A, Van Gestel\u00a0D, Ghanem\u00a0GE, Krayem\u00a0M (2023) The benefit of co-targeting PARP\u20111 and c\u2011Met on the efficacy of radiotherapy in wild type BRAF melanoma. Front Med 10:2023","journal-title":"Front Med"},{"issue":"4","key":"2501_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1541-7786.MCR-08-0358","volume":"7","author":"K Boisvert-Adamo","year":"2009","unstructured":"Boisvert-Adamo\u00a0K, Longmate\u00a0W, Abel\u00a0EV, Aplin\u00a0AE (2009) Mcl\u20111 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7(4):549\u2013556","journal-title":"Mol Cancer Res"},{"issue":"10","key":"2501_CR53","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1365-4632.2010.04777.x","volume":"51","author":"M Murphy","year":"2012","unstructured":"Murphy\u00a0M, Phelps\u00a0A, Swede\u00a0H, Claffey\u00a0K (2012) Hypoxia-induced response of cell cycle and apoptosis regulators in melanoma. Int J Dermatol 51(10):1263\u20131267","journal-title":"Int J Dermatol"},{"issue":"1","key":"2501_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/cancers13010102","volume":"13","author":"R Mart\u00ed-D\u00edaz","year":"2020","unstructured":"Mart\u00ed-D\u00edaz\u00a0R, Montenegro\u00a0MF, Cabezas-Herrera\u00a0J, Goding\u00a0CR, Rodr\u00edguez-L\u00f3pez\u00a0JN, S\u00e1nchez-del-Campo\u00a0L (2020) Acriflavine, a\u00a0potent inhibitor of HIF-1\u03b1, disturbs glucose metabolism and suppresses ATF4-protective pathways in melanoma under non-hypoxic conditions. Cancers 13(1):102","journal-title":"Cancers"},{"issue":"5","key":"2501_CR55","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/cdd.2014.24","volume":"21","author":"R Lall","year":"2014","unstructured":"Lall\u00a0R, Ganapathy\u00a0S, Yang\u00a0M, Xiao\u00a0S, Xu\u00a0T, Su\u00a0H, Shadfan\u00a0M, Asara\u00a0J, Ha\u00a0C, Ben-Sahra\u00a0I (2014) Low-dose radiation exposure induces a\u00a0HIF-1-mediated adaptive and protective metabolic response. Cell Death Differ 21(5):836\u2013844","journal-title":"Cell Death Differ"},{"issue":"6","key":"2501_CR56","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1172\/JCI80402","volume":"125","author":"KB Leszczynska","year":"2015","unstructured":"Leszczynska\u00a0KB, Foskolou\u00a0IP, Abraham\u00a0AG, Anbalagan\u00a0S, Tellier\u00a0C, Haider\u00a0S, Span\u00a0PN, O\u2019Neill\u00a0EE, Buffa\u00a0FM, Hammond\u00a0EM (2015) Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. J\u00a0Clin Invest 125(6):2385\u20132398","journal-title":"J Clin Invest"},{"issue":"1","key":"2501_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/0008-5472.CAN-03-2658","volume":"64","author":"EK Rofstad","year":"2004","unstructured":"Rofstad\u00a0EK, Mathiesen\u00a0B, Galappathi\u00a0K (2004) Increased Metastatic Dissemination in Human Melanoma Xenografts after Subcurative Radiation Treatment: Radiation-induced Increase in Fraction of Hypoxic Cells and Hypoxia-induced Up-Regulation of Urokinase-Type Plasminogen Activator Receptor. Cancer Res 64(1):13\u201318","journal-title":"Cancer Res"},{"issue":"1","key":"2501_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen\u00a0Z, Han\u00a0F, Du\u00a0Y, Shi\u00a0H, Zhou\u00a0W (2023) Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):70","journal-title":"Signal Transduct Target Ther"},{"key":"2501_CR59","doi-asserted-by":"crossref","unstructured":"Kabakov AE, Yakimova AO (2021) Hypoxia-Induced Cancer Cell Responses Driving Radioresistance of Hypoxic Tumors: Approaches to Targeting and Radiosensitizing. Cancers (basel) 13(5)","DOI":"10.3390\/cancers13051102"},{"issue":"5","key":"2501_CR60","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s10637-013-9928-9","volume":"31","author":"T Dasgupta","year":"2013","unstructured":"Dasgupta\u00a0T, Haas-Kogan\u00a0DA, Yang\u00a0X, Olow\u00a0A, Yang\u00a0DX, Gragg\u00a0A, Orloff\u00a0LA, Yom\u00a0SS (2013) Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs 31(5):1136\u20131141","journal-title":"Invest New Drugs"},{"issue":"1","key":"2501_CR61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13014-021-01903-5","volume":"16","author":"AR Wolfe","year":"2021","unstructured":"Wolfe\u00a0AR, Chablani\u00a0P, Siedow\u00a0MR, Miller\u00a0ED, Walston\u00a0S, Kendra\u00a0KL, Wuthrick\u00a0E, Williams\u00a0TM (2021) BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage\u00a0III melanoma. Radiat Oncol 16(1):181","journal-title":"Radiat Oncol"},{"key":"2501_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","volume":"73","author":"T Amaral","year":"2017","unstructured":"Amaral\u00a0T, Sinnberg\u00a0T, Meier\u00a0F, Krepler\u00a0C, Levesque\u00a0M, Niessner\u00a0H, Garbe\u00a0C (2017) The mitogen-activated protein kinase pathway in melanoma part\u00a0I\u2014Activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer 73:85\u201392","journal-title":"Eur J Cancer"},{"issue":"31","key":"2501_CR63","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1038\/s41388-021-01879-2","volume":"40","author":"J Alonso-Mara\u00f1\u00f3n","year":"2021","unstructured":"Alonso-Mara\u00f1\u00f3n\u00a0J, Villanueva\u00a0A, Piulats\u00a0JM, Mart\u00ednez-Iniesta\u00a0M, Sol\u00e9\u00a0L, Mart\u00edn-Liberal\u00a0J, Segura\u00a0S, Pujol\u00a0RM, Iglesias\u00a0M, Bigas\u00a0A, Gallardo\u00a0F, Espinosa\u00a0L (2021) Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair. Oncogene 40(31):5042\u20135048","journal-title":"Oncogene"},{"issue":"13","key":"2501_CR64","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.onc.1209994","volume":"26","author":"J Liu","year":"2007","unstructured":"Liu\u00a0J, Kumar\u00a0SK, Yu\u00a0D, Molton\u00a0S, McMahon\u00a0M, Herlyn\u00a0M, Thomas-Tikhonenko\u00a0A, Fuchs\u00a0S (2007) Oncogenic BRAF regulates \u03b2\u2011Trcp expression and NF-\u03baB activity in human melanoma cells. Oncogene 26(13):1954\u20131958","journal-title":"Oncogene"},{"issue":"14","key":"2501_CR65","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/onc.2013.131","volume":"33","author":"A Vultur","year":"2014","unstructured":"Vultur\u00a0A, Villanueva\u00a0J, Krepler\u00a0C, Rajan\u00a0G, Chen\u00a0Q, Xiao\u00a0M, Li\u00a0L, Gimotty\u00a0PA, Wilson\u00a0M, Hayden\u00a0J (2014) MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 33(14):1850\u20131861","journal-title":"Oncogene"},{"issue":"1","key":"2501_CR66","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41419-025-08036-7","volume":"16","author":"R Paudel","year":"2025","unstructured":"Paudel\u00a0R, Goller\u00a0S, Deutzmann\u00a0F, Gillitzer\u00a0A, Meder\u00a0K, Knorz\u00a0A, Schrama\u00a0D, Goebeler\u00a0M, Schmidt\u00a0M (2025) MEK5\/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D\/CDK4-mediated G1\/S progression. Cell Death Dis 16(1):689","journal-title":"Cell Death Dis"},{"issue":"17","key":"2501_CR67","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/0008-5472.CAN-18-0365","volume":"78","author":"TB Shabaneh","year":"2018","unstructured":"Shabaneh\u00a0TB, Molodtsov\u00a0AK, Steinberg\u00a0SM, Zhang\u00a0P, Torres\u00a0GM, Mohamed\u00a0GA, Boni\u00a0A, Curiel\u00a0TJ, Angeles\u00a0CV, Turk\u00a0MJ (2018) Oncogenic BRAF(V600E) Governs Regulatory T\u2011cell Recruitment during Melanoma Tumorigenesis. Cancer Res 78(17):5038\u20135049","journal-title":"Cancer Res"},{"issue":"12","key":"2501_CR68","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-13-3461","volume":"74","author":"PC Ho","year":"2014","unstructured":"Ho\u00a0PC, Meeth\u00a0KM, Tsui\u00a0YC, Srivastava\u00a0B, Bosenberg\u00a0MW, Kaech\u00a0SM (2014) Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFN\u03b3. Cancer Res 74(12):3205\u20133217","journal-title":"Cancer Res"},{"issue":"4","key":"2501_CR69","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/1744666X.2022.2044796","volume":"18","author":"R Adams","year":"2022","unstructured":"Adams\u00a0R, Coumbe\u00a0JEM, Coumbe\u00a0BGT, Thomas\u00a0J, Willsmore\u00a0Z, Dimitrievska\u00a0M, Yasuzawa-Parker\u00a0M, Hoyle\u00a0M, Ingar\u00a0S, Geh\u00a0JLC (2022) BRAF inhibitors and their immunological effects in malignant melanoma. Expert Rev Clin Immunol 18(4):347\u2013362","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2501_CR70","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert\u00a0C, Karaszewska\u00a0B, Schachter\u00a0J, Rutkowski\u00a0P, Mackiewicz\u00a0A, Stroiakovski\u00a0D, Lichinitser\u00a0M, Dummer\u00a0R, Grange\u00a0F, Mortier\u00a0L, Chiarion-Sileni\u00a0V, Drucis\u00a0K, Krajsova\u00a0I, Hauschild\u00a0A, Lorigan\u00a0P, Wolter\u00a0P, Long\u00a0GV, Flaherty\u00a0K, Nathan\u00a0P, Ribas\u00a0A, Martin\u00a0AM, Sun\u00a0P, Crist\u00a0W, Legos\u00a0J, Rubin\u00a0SD, Little\u00a0SM, Schadendorf\u00a0D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N\u00a0Engl J Med 372(1):30\u201339","journal-title":"N Engl J Med"},{"issue":"20","key":"2501_CR71","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin\u00a0J, Ascierto\u00a0PA, Dr\u00e9no\u00a0B, Atkinson\u00a0V, Liszkay\u00a0G, Maio\u00a0M, Mandal\u00e0\u00a0M, Demidov\u00a0L, Stroyakovskiy\u00a0D, Thomas\u00a0L, de la Cruz-Merino\u00a0L, Dutriaux\u00a0C, Garbe\u00a0C, Sovak\u00a0MA, Chang\u00a0I, Choong\u00a0N, Hack\u00a0SP, McArthur\u00a0GA, Ribas\u00a0A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N\u00a0Engl J Med 371(20):1867\u20131876","journal-title":"N Engl J Med"},{"issue":"6","key":"2501_CR72","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","volume":"26","author":"M Hecht","year":"2015","unstructured":"Hecht\u00a0M, Zimmer\u00a0L, Loquai\u00a0C, Weishaupt\u00a0C, Gutzmer\u00a0R, Schuster\u00a0B, Gleisner\u00a0S, Schulze\u00a0B, Goldinger\u00a0SM, Berking\u00a0C, Forschner\u00a0A, Clemens\u00a0P, Grabenbauer\u00a0G, M\u00fcller-Brenne\u00a0T, Bauch\u00a0J, Eich\u00a0HT, Grabbe\u00a0S, Schadendorf\u00a0D, Schuler\u00a0G, Keikavoussi\u00a0P, Semrau\u00a0S, Fietkau\u00a0R, Distel\u00a0LV, Heinzerling\u00a0L (2015) Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 26(6):1238\u20131244","journal-title":"Ann Oncol"},{"issue":"4","key":"2501_CR73","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","volume":"26","author":"KR Patel","year":"2016","unstructured":"Patel\u00a0KR, Chowdhary\u00a0M, Switchenko\u00a0JM, Kudchadkar\u00a0R, Lawson\u00a0DH, Cassidy\u00a0RJ, Prabhu\u00a0RS, Khan\u00a0MK (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26(4):387\u2013394","journal-title":"Melanoma Res"},{"issue":"6","key":"2501_CR74","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/bjc.2017.489","volume":"118","author":"M Hecht","year":"2018","unstructured":"Hecht\u00a0M, Meier\u00a0F, Zimmer\u00a0L, Polat\u00a0B, Loquai\u00a0C, Weishaupt\u00a0C, Forschner\u00a0A, Gutzmer\u00a0R, Utikal\u00a0JS, Goldinger\u00a0SM, Geier\u00a0M, Hassel\u00a0JC, Balermpas\u00a0P, Kiecker\u00a0F, Rauschenberg\u00a0R, Dietrich\u00a0U, Clemens\u00a0P, Berking\u00a0C, Grabenbauer\u00a0G, Schadendorf\u00a0D, Grabbe\u00a0S, Schuler\u00a0G, Fietkau\u00a0R, Distel\u00a0LV, Heinzerling\u00a0L (2018) Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. Br J Cancer 118(6):785\u2013792","journal-title":"Br J Cancer"},{"key":"2501_CR75","first-page":"95","volume":"30","author":"W Wang","year":"2021","unstructured":"Wang\u00a0W, Smith\u00a0JL, Carlino\u00a0MS, Burmeister\u00a0B, Pinkham\u00a0MB, Fogarty\u00a0GB, Christie\u00a0DRH, Estall\u00a0V, Shackleton\u00a0M, Clements\u00a0A, Wolfe\u00a0R, Thao\u00a0LTP, Paton\u00a0EJ, Steel\u00a0V, Williams\u00a0NC (2021) Phase\u00a0I\/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E\/K mutation-positive cutaneous Melanoma. Clin Transl Radiat Oncol 30:95\u201399","journal-title":"Clin Transl Radiat Oncol"},{"issue":"9","key":"2501_CR76","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/1346-8138.15962","volume":"48","author":"T Okuma","year":"2021","unstructured":"Okuma\u00a0T, Furudate\u00a0S, Kambayashi\u00a0Y, Hashimoto\u00a0A, Aiba\u00a0S, Fujimura\u00a0T (2021) Successful treatment of BRAF\/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy. J\u00a0Dermatol 48(9):1419\u20131422","journal-title":"J Dermatol"},{"key":"2501_CR77","first-page":"95","volume":"30","author":"W Wang","year":"2021","unstructured":"Wang\u00a0W, Smith\u00a0JL, Carlino\u00a0MS, Burmeister\u00a0B, Pinkham\u00a0MB, Fogarty\u00a0GB, Christie\u00a0DRH, Estall\u00a0V, Shackleton\u00a0M, Clements\u00a0A, Wolfe\u00a0R, Thao\u00a0LTP, Paton\u00a0EJ, Steel\u00a0V, Williams\u00a0NC (2021) Phase\u00a0I\/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E\/K mutation-positive cutaneous Melanoma. Clin Transl Radiat Oncol 30:95\u201399","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"2501_CR78","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/biomedicines11020394","volume":"11","author":"E Rossi","year":"2023","unstructured":"Rossi\u00a0E, Schinzari\u00a0G, Cellini\u00a0F, Balducci\u00a0M, Pasqualoni\u00a0M, Maiorano\u00a0BA, Fionda\u00a0B, Longo\u00a0S, Deodato\u00a0F, Di Stefani\u00a0A, Peris\u00a0K, Gambacorta\u00a0MA, Tortora\u00a0G (2023) Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma. Biomedicines 11(2):394","journal-title":"Biomedicines"},{"key":"2501_CR79","doi-asserted-by":"publisher","first-page":"113287","DOI":"10.1016\/j.ejca.2023.113287","volume":"192","author":"AE Dohm","year":"2023","unstructured":"Dohm\u00a0AE, Nakashima\u00a0JY, Kalagotla\u00a0H, Jiang\u00a0SX, Tang\u00a0JD, Bhandari\u00a0M, Kim\u00a0Y, Graham\u00a0JA, Khushalani\u00a0NI, Forsyth\u00a0PA, Etame\u00a0AB, Liu\u00a0JK, Tran\u00a0ND, Vogelbaum\u00a0MA, Wuthrick\u00a0EJ, H\u2011HM YODE, Ahmed\u00a0KA (2023) Stereotactic radiosurgery and anti-PD\u20111 + CTLA-4\u00a0therapy, anti-PD-1\u00a0therapy, anti-CTLA-4\u00a0therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. Eur J Cancer 192:113287","journal-title":"Eur J Cancer"},{"issue":"11","key":"2501_CR80","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1093\/neuonc\/noae116","volume":"26","author":"I M\u00e1rquez-Rodas","year":"2024","unstructured":"M\u00e1rquez-Rodas\u00a0I, \u00c1lvarez\u00a0A, Arance\u00a0A, Valduvieco\u00a0I, Berciano-Guerrero\u00a0M, Delgado\u00a0R, Soria\u00a0A, Lopez Campos\u00a0F, S\u00e1nchez\u00a0P, Romero\u00a0JL, Martin-Liberal\u00a0J, Lucas\u00a0A, D\u00edaz-Beveridge\u00a0R, Conde-Moreno\u00a0AJ, \u00c1lamo de la Gala\u00a0MDC, Garc\u00eda-Casta\u00f1o\u00a0A, Prada\u00a0PJ, Gonz\u00e1lez\u00a0CM, Puertas\u00a0E, Vidal\u00a0J, Foro\u00a0P, Aguado de la Rosa\u00a0C, Corona\u00a0JA, Cerezuela-Fuentes\u00a0P, L\u00f3pez\u00a0P, Luna\u00a0P, Aymar\u00a0N, Pu\u00e9rtolas\u00a0T, Sanagust\u00edn\u00a0P, Berrocal\u00a0A (2024) Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN\/GEM1802 phase\u00a0II study). Neuro Oncol 26(11):2074\u20132083","journal-title":"Neuro Oncol"},{"issue":"6","key":"2501_CR81","first-page":"374","volume":"175","author":"C Battilotti","year":"2024","unstructured":"Battilotti\u00a0C, Proietti\u00a0I, Svara\u00a0F, Rizzuto\u00a0G, Tolino\u00a0E, Bernardini\u00a0N, Skroza\u00a0N, Filippi\u00a0L, Potenza\u00a0C (2024) Safe Integration of Encorafenib plus Binimetinib with Stereotactic Radiosurgery for Melanoma Brain Metastases: a\u00a0Case Report. Clin Ter 175(6):374\u2013377","journal-title":"Clin Ter"},{"issue":"6","key":"2501_CR82","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CMR.0000000000000682","volume":"30","author":"JS Ziegler","year":"2020","unstructured":"Ziegler\u00a0JS, Kroeze\u00a0S, Hilbers\u00a0ML, Imhof\u00a0L, Guckenberger\u00a0M, Levesque\u00a0MP, Dummer\u00a0R, Cheng\u00a0P, Mangana\u00a0J (2020) Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a\u00a0single-center retrospective analysis. Melanoma Res 30(6):552\u2013561","journal-title":"Melanoma Res"},{"issue":"6","key":"2501_CR83","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/bjc.2017.489","volume":"118","author":"M Hecht","year":"2018","unstructured":"Hecht\u00a0M, Meier\u00a0F, Zimmer\u00a0L, Polat\u00a0B, Loquai\u00a0C, Weishaupt\u00a0C, Forschner\u00a0A, Gutzmer\u00a0R, Utikal\u00a0JS, Goldinger\u00a0SM, Geier\u00a0M, Hassel\u00a0JC, Balermpas\u00a0P, Kiecker\u00a0F, Rauschenberg\u00a0R, Dietrich\u00a0U, Clemens\u00a0P, Berking\u00a0C, Grabenbauer\u00a0G, Schadendorf\u00a0D, Grabbe\u00a0S, Schuler\u00a0G, Fietkau\u00a0R, Distel\u00a0LV, Heinzerling\u00a0L (2018) Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. Br J Cancer 118(6):785\u2013792","journal-title":"Br J Cancer"},{"issue":"2","key":"2501_CR84","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ijrobp.2016.01.038","volume":"95","author":"CJ Anker","year":"2016","unstructured":"Anker\u00a0CJ, Grossmann\u00a0KF, Atkins\u00a0MB, Suneja\u00a0G, Tarhini\u00a0AA, Kirkwood\u00a0JM (2016) Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 95(2):632\u2013646","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2501_CR85","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3390\/cancers13061421","volume":"13","author":"H Akil","year":"2021","unstructured":"Akil\u00a0H, Quintana\u00a0M, Raymond\u00a0JH, Billoux\u00a0T, Benboubker\u00a0V, Besse\u00a0S, Auzeloux\u00a0P, Delmas\u00a0V, Petit\u00a0V, Larue\u00a0L, D\u2019Incan\u00a0M, Degoul\u00a0F, Rouanet\u00a0J (2021) Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. Cancers 13(6):1421","journal-title":"Cancers"},{"issue":"6","key":"2501_CR86","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ijc.34807","volume":"154","author":"L Dinter","year":"2024","unstructured":"Dinter\u00a0L, Karitzky\u00a0PC, Schulz\u00a0A, Wurm\u00a0AA, Mehnert\u00a0MC, Sergon\u00a0M, Tunger\u00a0A, Lesche\u00a0M, Wehner\u00a0R, M\u00fcller\u00a0A, K\u00e4ubler\u00a0T, Niessner\u00a0H, Dahl\u00a0A, Beissert\u00a0S, Schmitz\u00a0M, Meier\u00a0F, Seliger\u00a0B, Westphal\u00a0D (2024) BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms. Int J Cancer 154(6):1057\u20131072","journal-title":"Int J Cancer"},{"key":"2501_CR87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely\u00a0MD, Zhang\u00a0T, Chen\u00a0L (2022) Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol 40:45\u201374","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"2501_CR88","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker\u00a0HE, Paget\u00a0JT, Khan\u00a0AA, Harrington\u00a0KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15(7):409\u2013425","journal-title":"Nat Rev Cancer"},{"key":"2501_CR89","first-page":"5","volume":"9","author":"R Chicas-Sett","year":"2018","unstructured":"Chicas-Sett\u00a0R, Morales-Orue\u00a0I, Rodriguez-Abreu\u00a0D, Lara-Jimenez\u00a0P (2018) Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A\u00a0systematic review. Clin Transl Radiat Oncol 9:5\u201311","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"2501_CR90","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/cells10040930","volume":"10","author":"RD Vaes","year":"2021","unstructured":"Vaes\u00a0RD, Hendriks\u00a0LE, Vooijs\u00a0M, De Ruysscher\u00a0D (2021) Biomarkers of radiotherapy-induced immunogenic cell death. Cells 10(4):930","journal-title":"Cells"},{"issue":"21","key":"2501_CR91","doi-asserted-by":"publisher","first-page":"11621","DOI":"10.3390\/ijms222111621","volume":"22","author":"M Rodr\u00edguez Pl\u00e1","year":"2021","unstructured":"Rodr\u00edguez Pl\u00e1\u00a0M, Dualde Beltr\u00e1n\u00a0D, Ferrer Albiach\u00a0E (2021) Immune checkpoints inhibitors and SRS\/SBRT synergy in metastatic non-small-cell lung cancer and melanoma: a\u00a0systematic review. Int J Mol Sci 22(21):11621","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2501_CR92","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen\u00a0Y, Gao\u00a0M, Huang\u00a0Z, Yu\u00a0J, Meng\u00a0X (2020) SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a\u00a0focus on the mechanisms, advances, and future challenges. J\u00a0Hematol Oncol 13(1):105","journal-title":"J Hematol Oncol"},{"key":"2501_CR93","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3389\/fimmu.2016.00610","volume":"7","author":"A Derer","year":"2016","unstructured":"Derer\u00a0A, Spiljar\u00a0M, B\u00e4umler\u00a0M, Hecht\u00a0M, Fietkau\u00a0R, Frey\u00a0B, Gaipl\u00a0US (2016) Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol 7:610","journal-title":"Front Immunol"},{"issue":"7547","key":"2501_CR94","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor\u00a0C, Rech\u00a0AJ, Maity\u00a0A, Rengan\u00a0R, Pauken\u00a0KE, Stelekati\u00a0E, Benci\u00a0JL, Xu\u00a0B, Dada\u00a0H, Odorizzi\u00a0PM, Herati\u00a0RS, Mansfield\u00a0KD, Patsch\u00a0D, Amaravadi\u00a0RK, Schuchter\u00a0LM, Ishwaran\u00a0H, Mick\u00a0R, Pryma\u00a0DA, Xu\u00a0X, Feldman\u00a0MD, Gangadhar\u00a0TC, Hahn\u00a0SM, Wherry\u00a0EJ, Vonderheide\u00a0RH, Minn\u00a0AJ (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547):373\u2013377","journal-title":"Nature"},{"issue":"6","key":"2501_CR95","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00262-016-1843-4","volume":"65","author":"P Kroon","year":"2016","unstructured":"Kroon\u00a0P, Gadiot\u00a0J, Peeters\u00a0M, Gasparini\u00a0A, Deken\u00a0MA, Yagita\u00a0H, Verheij\u00a0M, Borst\u00a0J, Blank\u00a0CU, Verbrugge\u00a0I (2016) Concomitant targeting of programmed death\u20111 (PD-1) and CD137 improves the efficacy of radiotherapy in a\u00a0mouse model of human BRAFV600-mutant melanoma. Cancer Immunol Immunother 65(6):753\u2013763","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2501_CR96","doi-asserted-by":"publisher","first-page":"2057892","DOI":"10.1080\/2162402X.2022.2057892","volume":"11","author":"H Zhou","year":"2022","unstructured":"Zhou\u00a0H, Tu\u00a0C, Yang\u00a0P, Li\u00a0J, Kepp\u00a0O, Li\u00a0H, Zhang\u00a0L, Zhang\u00a0L, Zhao\u00a0Y, Zhang\u00a0T, Sheng\u00a0C, Wang\u00a0J (2022) Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1\u00a0therapy in mice. OncoImmunology 11(1):2057892","journal-title":"OncoImmunology"},{"issue":"1","key":"2501_CR97","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41420-021-00731-6","volume":"7","author":"H Zhou","year":"2021","unstructured":"Zhou\u00a0H, Yang\u00a0P, Li\u00a0H, Zhang\u00a0L, Li\u00a0J, Zhang\u00a0T, Sheng\u00a0C, Wang\u00a0J (2021) Carbon ion radiotherapy boosts anti-tumour immune responses by inhibiting myeloid-derived suppressor cells in melanoma-bearing mice. Cell Death Discov 7(1):332","journal-title":"Cell Death Discov"},{"key":"2501_CR98","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.radonc.2019.06.013","volume":"138","author":"YM Mowery","year":"2019","unstructured":"Mowery\u00a0YM, Patel\u00a0K, Chowdhary\u00a0M, Rushing\u00a0CN, Choudhury\u00a0RK, Lowe\u00a0JR, Olson\u00a0AC, Wisdom\u00a0AJ, Salama\u00a0JK, Hanks\u00a0BA, Khan\u00a0MK, Salama\u00a0AKS (2019) Retrospective analysis of safety and efficacy of anti-PD-1\u00a0therapy and radiation therapy in advanced melanoma: A\u00a0bi-institutional study. Radiother Oncol 138:114\u2013120","journal-title":"Radiother Oncol"},{"issue":"1","key":"2501_CR99","doi-asserted-by":"publisher","first-page":"1863631","DOI":"10.1080\/2162402X.2020.1863631","volume":"10","author":"A Maity","year":"2021","unstructured":"Maity\u00a0A, Mick\u00a0R, Rengan\u00a0R, Mitchell\u00a0TC, Amaravadi\u00a0RK, Schuchter\u00a0LM, Pryma\u00a0DA, Patsch\u00a0DM, Maity\u00a0AP, Minn\u00a0AJ, Vonderheide\u00a0RH, Lukens\u00a0JN (2021) A\u00a0stratified phase\u00a0I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. OncoImmunology 10(1):1863631","journal-title":"OncoImmunology"},{"issue":"4","key":"2501_CR100","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ijrobp.2017.11.029","volume":"100","author":"N Sundahl","year":"2018","unstructured":"Sundahl\u00a0N, De Wolf\u00a0K, Kruse\u00a0V, Meireson\u00a0A, Reynders\u00a0D, Goetghebeur\u00a0E, Van Gele\u00a0M, Speeckaert\u00a0R, Hennart\u00a0B, Brochez\u00a0L (2018) Phase\u00a01 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma. Int J Radiat Oncol Biol Phys 100(4):906\u2013915","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2501_CR101","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","volume":"96","author":"SM Hiniker","year":"2016","unstructured":"Hiniker\u00a0SM, Reddy\u00a0SA, Maecker\u00a0HT, Subrahmanyam\u00a0PB, Rosenberg-Hasson\u00a0Y, Swetter\u00a0SM, Saha\u00a0S, Shura\u00a0L, Knox\u00a0SJ (2016) A\u00a0Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys 96(3):578\u2013588","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2501_CR102","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1038\/s41467-025-57865-9","volume":"16","author":"JJ Orme","year":"2025","unstructured":"Orme\u00a0JJ, Zhang\u00a0H, Lingamaneni\u00a0P, Kim\u00a0Y, Lavoie\u00a0R, Dorr\u00a0M, Dizona\u00a0P, Hirdler\u00a0J, Bering\u00a0EA, Gicobi\u00a0JK, Hsu\u00a0M, Dale\u00a0H, Childs\u00a0DS, Kottschade\u00a0LA, McWilliams\u00a0RR, Block\u00a0MS, Mansfield\u00a0AS, Markovic\u00a0SN, Olivier\u00a0K, Owen\u00a0D, Lester\u00a0S, Ma\u00a0D, Dronca\u00a0RS, Dong\u00a0H, Lucien\u00a0F, Packard\u00a0AT, Winters\u00a0JL, Park\u00a0SS (2025) Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a\u00a0phase\u00a0I trial. Nat Commun 16(1):2507","journal-title":"Nat Commun"},{"issue":"3","key":"2501_CR103","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.ijrobp.2020.07.2217","volume":"108","author":"RC Sett","year":"2020","unstructured":"Sett\u00a0RC, Martin\u00a0JZ, Martinez\u00a0JC, Morales\u00a0I, Rodriguez\u00a0D, Benitez\u00a0G, Lloret\u00a0M, Lara\u00a0P (2020) Immuno-SABR reboots the immune response in patients with metastatic NSCLC and melanoma in progression to anti-PD-1\u00a0therapy. Int J Radiat Oncol Biol Phys 108(3):S73\u2013S74","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2501_CR104","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ijrobp.2019.03.041","volume":"104","author":"N Sundahl","year":"2019","unstructured":"Sundahl\u00a0N, Seremet\u00a0T, Van Dorpe\u00a0J, Neyns\u00a0B, Ferdinande\u00a0L, Meireson\u00a0A, Brochez\u00a0L, Kruse\u00a0V, Ost\u00a0P (2019) Phase\u00a02\u00a0trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. Int J Radiat Oncol Biol Phys 104(4):828\u2013835","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2501_CR105","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00262-024-03751-0","volume":"73","author":"M Vounckx","year":"2024","unstructured":"Vounckx\u00a0M, Tijtgat\u00a0J, Stevens\u00a0L, Dirven\u00a0I, Ilsen\u00a0B, Vandenbroucke\u00a0F, Raeymaeckers\u00a0S, Vekens\u00a0K, Forsyth\u00a0R, Geeraerts\u00a0X (2024) A\u00a0randomized phase\u00a0II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab\/ipilimumab plus CD1c (BDCA-1)+\/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors. Cancer Immunol Immunother 73(9):167","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2501_CR106","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-019-0588-y","volume":"7","author":"G Minniti","year":"2019","unstructured":"Minniti\u00a0G, Anzellini\u00a0D, Reverberi\u00a0C, Cappellini\u00a0GCA, Marchetti\u00a0L, Bianciardi\u00a0F, Bozzao\u00a0A, Osti\u00a0M, Gentile\u00a0PC, Esposito\u00a0V (2019) Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. J\u00a0Immunother Cancer 7(1):102","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2501_CR107","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1078155216635853","volume":"23","author":"CA Dasanu","year":"2017","unstructured":"Dasanu\u00a0CA, Jen\u00a0T, Skulski\u00a0R (2017) Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J\u00a0Oncol Pharm Pract 23(3):231\u2013234","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"2501_CR108","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","volume":"14","author":"M Altan","year":"2019","unstructured":"Altan\u00a0M, Toki\u00a0MI, Gettinger\u00a0SN, Carvajal-Hausdorf\u00a0DE, Zugazagoitia\u00a0J, Sinard\u00a0JH, Herbst\u00a0RS, Rimm\u00a0DL (2019) Immune Checkpoint Inhibitor-Associated Pericarditis. J\u00a0Thorac Oncol 14(6):1102\u20131108","journal-title":"J Thorac Oncol"},{"key":"2501_CR109","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","volume":"10","author":"Q Su","year":"2019","unstructured":"Su\u00a0Q, Zhu\u00a0EC, J\u2011b WLT, Y\u2011l H, D\u2011y W, Z\u2011h G (2019) Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a\u00a0systematic review and meta-analysis. Front Immunol 10:108","journal-title":"Front Immunol"},{"key":"2501_CR110","doi-asserted-by":"publisher","first-page":"794615","DOI":"10.3389\/fonc.2021.794615","volume":"11","author":"AM Burke","year":"2021","unstructured":"Burke\u00a0AM, Carrasquilla\u00a0M, Jean\u00a0WC, Collins\u00a0BT, Anaizi\u00a0AN, Atkins\u00a0MB, Gibney\u00a0GT, Collins\u00a0SP (2021) Volume of Disease as a\u00a0Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy. Front Oncol 11:794615","journal-title":"Front Oncol"},{"issue":"3","key":"2501_CR111","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11060-023-04543-9","volume":"166","author":"JD Tang","year":"2024","unstructured":"Tang\u00a0JD, Mills\u00a0MN, Nakashima\u00a0J, Dohm\u00a0AE, Khushalani\u00a0NI, Forsyth\u00a0PA, Vogelbaum\u00a0MA, Wuthrick\u00a0EJ, H\u2011HM YODE, Liu\u00a0JKC, Ahmed\u00a0KA (2024) Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery. J\u00a0Neurooncol 166(3):431\u2013440","journal-title":"J Neurooncol"},{"key":"2501_CR112","first-page":"100573","volume":"39","author":"R Bodensohn","year":"2023","unstructured":"Bodensohn\u00a0R, Werner\u00a0S, Reis\u00a0J, Pazos Escudero\u00a0M, Kaempfel\u00a0AL, Hadi\u00a0I, Forbrig\u00a0R, Manapov\u00a0F, Corradini\u00a0S, Belka\u00a0C, Theurich\u00a0S, Heinzerling\u00a0L, Schlaak\u00a0M, Niyazi\u00a0M (2023) Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A\u00a0retrospective monocentric toxicity analysis. Clin Transl Radiat Oncol 39:100573","journal-title":"Clin Transl Radiat Oncol"},{"issue":"9","key":"2501_CR113","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1007\/s12094-022-02838-3","volume":"24","author":"DG de Castro","year":"2022","unstructured":"de Castro\u00a0DG, Teixeira\u00a0CHA, Gondim\u00a0GRM, Aguilar\u00a0PB, MAd Jorge Morais Hanriot Rd\u00a0CSBTWC (2022) Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a\u00a0real-world evidence. Clin Transl Oncol 24(9):1828\u20131830","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"2501_CR114","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-020-03663-w","volume":"152","author":"RE Wegner","year":"2021","unstructured":"Wegner\u00a0RE, Abel\u00a0S, D\u2019Amico\u00a0RS, Mehta\u00a0GU, Sheehan\u00a0J (2021) Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome. J\u00a0Neurooncol 152(1):79\u201387","journal-title":"J Neurooncol"},{"issue":"3, Supplement","key":"2501_CR115","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1016\/j.ijrobp.2021.07.1542","volume":"111","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer\u00a0EJ, Gurewitz\u00a0J, Malouff\u00a0TD, Bernstein\u00a0K, Kondziolka\u00a0D, Bonney\u00a0P, Patel\u00a0SI, Palmer\u00a0JD, Fakhoury\u00a0K, Rusthoven\u00a0CG, Mathieu\u00a0D, Deibert\u00a0C, Picozzi\u00a0P, Jones\u00a0B, Lee\u00a0CC, Sharma\u00a0S, Niranjan\u00a0A, Sheehan\u00a0JP, Ahluwalia\u00a0M, Trifiletti\u00a0DM (2021) Concurrent vs. Sequential Stereotactic Radiosurgery and Immune Checkpoint Inhibition in Melanoma Brain Metastases: An International Cooperative Group Study. Int J Radiat Oncol 111(3, Supplement):e571\u2013e572","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"2501_CR116","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1016\/j.ijrobp.2022.07.796","volume":"114","author":"T Kleber","year":"2022","unstructured":"Kleber\u00a0T, Switchenko\u00a0J, Lawson\u00a0D, Buchwald\u00a0ZS, Khan\u00a0MK (2022) Real World Outcomes of Melanoma Brain Metastases Treated with Immunotherapy with or without Stereotactic Radiosurgery. Int J Radiat Oncol Biol Phys 114(3):e56","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2501_CR117","doi-asserted-by":"publisher","first-page":"110910","DOI":"10.1016\/j.radonc.2025.110910","volume":"208","author":"ESM van Aken","year":"2025","unstructured":"van Aken\u00a0ESM, Devnani\u00a0B, Castelo-Branco\u00a0L, De Ruysscher\u00a0D, Martins-Branco\u00a0D, Marijnen\u00a0CAM, Muoio\u00a0B, Belka\u00a0C, Lordick\u00a0F, Kroeze\u00a0S, Pentheroudakis\u00a0G, Trapani\u00a0D, Ricardi\u00a0U, Gandhi\u00a0AK, Prelaj\u00a0A, O\u2019Cathail\u00a0SM, de Jong\u00a0MC (2025) ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy. Radiother Oncol 208:110910","journal-title":"Radiother Oncol"},{"issue":"2","key":"2501_CR118","first-page":"e1470","volume":"5","author":"ES van Aken","year":"2022","unstructured":"van Aken\u00a0ES, Beeker\u00a0A, Houtenbos\u00a0I, Pos\u00a0FJ, Linn\u00a0SC, Elkhuizen\u00a0PH, de Jong\u00a0MC (2022) Unexpected toxicity of CDK4\/6 inhibitor palbociclib and radiotherapy. Cancer Rep 5(2):e1470","journal-title":"Cancer Rep"},{"issue":"5","key":"2501_CR119","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","volume":"27","author":"R de Haan","year":"2021","unstructured":"de Haan\u00a0R, van den Heuvel\u00a0MM, van Diessen\u00a0J, Peulen\u00a0HM, van Werkhoven\u00a0E, de Langen\u00a0AJ, Lalezari\u00a0F, Pluim\u00a0D, Verwijs-Janssen\u00a0M, Vens\u00a0C (2021) Phase\u00a0I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer. Clin Cancer Res 27(5):1256\u20131266","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2501_CR120","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/bjc.2017.489","volume":"118","author":"M Hecht","year":"2018","unstructured":"Hecht\u00a0M, Meier\u00a0F, Zimmer\u00a0L, Polat\u00a0B, Loquai\u00a0C, Weishaupt\u00a0C, Forschner\u00a0A, Gutzmer\u00a0R, Utikal\u00a0JS, Goldinger\u00a0SM (2018) Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. Br J Cancer 118(6):785\u2013792","journal-title":"Br J Cancer"},{"key":"2501_CR121","first-page":"93","volume":"33","author":"ES van Aken","year":"2022","unstructured":"van Aken\u00a0ES, van der Linden\u00a0YM, van Thienen\u00a0JV, de Langen\u00a0AJ, Marijnen\u00a0CA, de Jong\u00a0MC (2022) Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges. Clin Transl Radiat Oncol 33:93\u201398","journal-title":"Clin Transl Radiat Oncol"},{"issue":"8","key":"2501_CR122","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11912-019-0818-y","volume":"21","author":"FS Ali","year":"2019","unstructured":"Ali\u00a0FS, Arevalo\u00a0O, Zorofchian\u00a0S, Patrizz\u00a0A, Riascos\u00a0R, Tandon\u00a0N, Blanco\u00a0A, Ballester\u00a0LY, Esquenazi\u00a0Y (2019) Cerebral radiation necrosis: incidence, pathogenesis, diagnostic challenges, and future opportunities. Curr Oncol Reports 21(8):66","journal-title":"Curr Oncol Reports"},{"key":"2501_CR123","doi-asserted-by":"crossref","unstructured":"Martorana F, Da Silva LA, Sessa C, Colombo I (2022) Everything Comes with a\u00a0Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. Cancers (basel) 14(4)","DOI":"10.3390\/cancers14040953"},{"key":"2501_CR124","doi-asserted-by":"publisher","first-page":"104811","DOI":"10.1016\/j.critrevonc.2025.104811","volume":"214","author":"BHG van Riet","year":"2025","unstructured":"van Riet\u00a0BHG, Venneker\u00a0S, Bov\u00e9e\u00a0JVMG, Steeghs\u00a0N, Haas\u00a0RL (2025) Targeting the DNA damage response to enhance radiotherapy in soft tissue sarcomas. Crit Rev Oncol Hematol 214:104811","journal-title":"Crit Rev Oncol Hematol"},{"key":"2501_CR125","doi-asserted-by":"publisher","first-page":"804212","DOI":"10.3389\/fonc.2022.804212","volume":"12","author":"Y Li","year":"2022","unstructured":"Li\u00a0Y, Fu\u00a0R, Jiang\u00a0T, Duan\u00a0D, Wu\u00a0Y, Li\u00a0C, Li\u00a0Z, Ni\u00a0R, Li\u00a0L, Liu\u00a0Y (2022) Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies. Front Oncol 12:804212","journal-title":"Front Oncol"},{"issue":"5","key":"2501_CR126","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/CAD.0000000000000349","volume":"27","author":"J Langrand-Escure","year":"2016","unstructured":"Langrand-Escure\u00a0J, Vallard\u00a0A, Rivoirard\u00a0R, M\u00e9ry\u00a0B, Guy\u00a0J\u2011B, Espenel\u00a0S, Trone\u00a0J\u2011C, Mrad\u00a0MB, Diao\u00a0P, Rancoule\u00a0C (2016) Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a\u00a0real-life report. Anticancer Drugs 27(5):427\u2013432","journal-title":"Anticancer Drugs"},{"key":"2501_CR127","doi-asserted-by":"crossref","unstructured":"van Aken ESM, Devnani B, Prelaj A, Castelo-Branco L, Marijnen CAM, Martins-Branco D, Gambacorta MA, Lamarca A, Harrington K, Minniti G, Hecht M, Papamichael D, Krause M, Cathomas R, Lindberg K, O\u2019Cathail SM, Nestle U, Barriuso J, Nowicki S, R\u00f6del C, Boot P, Belka C, Ricardi U, Lordick F, De Ruysscher D, Pentheroudakis G, de Jong MC, Gandhi AK (2025) ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors. Ann Oncol","DOI":"10.1016\/j.annonc.2025.09.008"},{"key":"2501_CR128","doi-asserted-by":"publisher","first-page":"102090","DOI":"10.1016\/j.ctrv.2020.102090","volume":"90","author":"L Carrassa","year":"2020","unstructured":"Carrassa\u00a0L, Colombo\u00a0I, Damia\u00a0G, Bertoni\u00a0F (2020) Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. Cancer Treat Rev 90:102090","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"2501_CR129","doi-asserted-by":"publisher","first-page":"e70180","DOI":"10.1002\/jbt.70180","volume":"39","author":"FA Muhammad","year":"2025","unstructured":"Muhammad\u00a0FA, Adhab\u00a0AH, Mahdi\u00a0MS, Jain\u00a0V, Ganesan\u00a0S, Bhanot\u00a0D, Naidu\u00a0KS, Kaur\u00a0S, Mansoor\u00a0AS, Radi\u00a0UK (2025) Unveiling Novel Targets in Lung Tumors for Enhanced Radiotherapy Efficacy: A\u00a0Comprehensive Review. J\u00a0Biochem Mol Toxicol 39(3):e70180","journal-title":"J Biochem Mol Toxicol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02501-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02501-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02501-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:03:39Z","timestamp":1777035819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02501-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2501"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02501-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.A.\u00a0Aseeri, Z.\u00a0AlKhafaje, U.\u00a0Abdul-Reda Hussein, Z.\u00a0Adel, O.K.A.\u00a0Alkadir, A.\u00a0Aldulaimi, S.\u00a0Mahmood Saeed, W.M.\u00a0Taher, M.\u00a0Alwan, and A.\u00a0Smerat declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Ethical approval: not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}